NeoGenomics Inc

NeoGenomics Inc. will release Q4 & full‑year 2025 results on Feb 17, 2026—key insights on revenue growth, margin gains, and capital plans for investors.

NeoGenomics, Inc. delivers cutting‑edge cancer genetics diagnostics amid volatile biotech markets, offering comprehensive lab services for pathologists, oncologists, and hospitals.

NeoGenomics Inc. boosts 2026 earnings outlook with strong Q4 revenue, “Buy” upgrade and Green Level 5 certification, positioning it as a leader in precision oncology diagnostics.

NeoGenomics forecasts $190 M Q4 2025 revenue and $727 M yearly, while a CFO transition bolsters its precision‑medicine growth momentum.

NeoGenomics Inc. has seen its stock price and price target cut due to concerns over its performance, but the company is taking steps to manage debt and drive growth through new product launches and strategic initiatives.

NeoGenomics Inc. is navigating a challenging financial landscape with mixed market reaction to recent developments, including debt repayment and revenue growth, but faces ongoing concerns about its growth trajectory.

NeoGenomics reports an 8% revenue increase in Q1 2025, despite market challenges, driven by strategic advancements and a new partnership with Ultima Genomics.

NeoGenomics Inc. has announced a strategic collaboration with Ultima Genomics to enhance its oncology diagnostic capabilities through the use of Ultima’s cutting-edge sequencing platform.

NeoGenomics Inc. is a leader in cancer genetics diagnostic testing services, with a commitment to innovation and excellence that positions it for future growth in the rapidly evolving healthcare sector.